ILMN Stock: Price, Earnings History and SEC Filings
Illumina, Inc. (ILMN) last traded at $235.99, down 18.64% on the latest session and down 13.8% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $1.44 against an analyst estimate of $1.36, a beat of 5.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ILMN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $1.44 | $1.36 | +5.88% |
| Jun 2026 | Jul 30, 2026 | $1.31 | $1.23 | +6.50% |
| Mar 2026 | Apr 30, 2026 | $1.15 | $1.05 | +9.52% |
| Dec 2025 | Feb 5, 2026 | $1.35 | $1.26 | +7.14% |
ILMN beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How ILMN reacts to earnings
Across its last 8 earnings releases, ILMN moved 9.3% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | After close | -18.64% |
| 2026-07-30 | After close | +0.00% |
| 2026-04-30 | After close | +7.13% |
| 2026-02-05 | After close | -10.40% |
| 2026-01-13 | Before open | +0.99% |
| 2025-10-30 | After close | +24.78% |
| 2025-07-31 | After close | -7.84% |
| 2025-05-08 | After close | -4.80% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ILMN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $4.3B | $850M | $931M | 19.6% | $5.45 |
| 2024 | $4.4B | -$1.2B | $709M | -28.0% | $-7.69 |
| 2023 | $4.5B | -$1.2B | $283M | -25.8% | $-7.34 |
| 2022 | $4.5B | $762M | $337M | 16.8% | $5.04 |
| 2021 | $3.2B | $656M | $891M | 20.3% | $4.45 |
| 2019 | $3.5B | $1.0B | $842M | 28.3% | $6.74 |
| 2018 | $3.3B | $826M | $846M | 24.8% | $5.56 |
| 2017 | $2.8B | $726M | $565M | 26.4% | $4.92 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ILMN
- 10-Q · Oct 30, 2026
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 8-K · Oct 13, 2026Material agreement, New financial obligation, Financial statements and exhibits
- 8-K · Aug 17, 2026Other events, Financial statements and exhibits
- 8-K · Aug 13, 2026Material agreement, Agreement terminated, New financial obligation
- 424B2 · Aug 12, 2026
- 8-K · Aug 12, 2026Other events, Financial statements and exhibits
- 424B2 · Aug 10, 2026
- 8-K · Aug 7, 2026Other events, Financial statements and exhibits
- 10-Q · Jul 31, 2026
Insider filing activity
ILMN insiders filed 11 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ILMN news
- Illumina (ILMN) Stock Falls After Q3 Results Lift GuidanceNov 1, 2026 · finance.yahoo.com
- Why Illumina (ILMN) shares are getting obliterated todayOct 31, 2026 · finance.yahoo.com
- Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3Oct 31, 2026 · stocktwits.com
- Illumina (ILMN) Stock Stays Reasonable After Raised 2026 GuidanceOct 31, 2026 · finance.yahoo.com
- Illumina CEO on Q3 Results and Business OutlookOct 30, 2026 · finance.yahoo.com
- Illumina (ILMN) Lifts Outlook Following Q3 Results But Valuation Still Looks StretchedOct 30, 2026 · finance.yahoo.com
- Illumina Crashes As Tariffs, AI Woes Eat Into 157% Run-UpOct 30, 2026 · finance.yahoo.com
- Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AIOct 30, 2026 · finance.yahoo.com
About Illumina, Inc.
Illumina, Inc. (ILMN) is a US-listed public company on Nasdaq. The SEC classifies its business as Laboratory Analytical Instruments. It is incorporated in DE. Its fiscal year ends in January.